Your browser doesn't support javascript.
loading
Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trial.
Gao, Leili; Cheng, Zhifeng; Su, Benli; Su, Xiuhai; Song, Weihong; Guo, Yushan; Liao, Lin; Chen, Xiaowen; Li, Jiarui; Tan, Xingrong; Xu, Fangjiang; Pang, Shuguang; Wang, Kun; Ye, Jun; Wang, Yuan; Chen, Lili; Sun, Jingfang; Ji, Linong.
Afiliação
  • Gao L; Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
  • Cheng Z; Department of Endocrinology, Fourth Affiliated Hospital of Harbin Medical University, Harbin, China.
  • Su B; Department of Endocrinology, The Second Hospital of Dalian Medical University, Dalian, China.
  • Su X; Department of Endocrinology, Cangzhou Hospital of Integrated TCM-WM Hebei, Cangzhou, China.
  • Song W; Department of Endocrinology, Chenzhou First People's Hospital, Chenzhou, China.
  • Guo Y; Department of Endocrinology, The Affiliated Hospital of Beihua University, Jilin, China.
  • Liao L; Department of Endocrinology, Shandong Provincial Qianfoshan Hospital, Jinan, China.
  • Chen X; Department of Endocrinology, Huangshi Central Hospital, Huangshi, China.
  • Li J; Department of Endocrinology, Cangzhou Central Hospital, Cangzhou, China.
  • Tan X; Department of Endocrinology, The Ninth People's Hospital of Chongqing, Chongqing, China.
  • Xu F; Department of Endocrinology, Linyi Central Hospital, Linyi, China.
  • Pang S; Department of Endocrinology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China.
  • Wang K; Department of Endocrinology, Nanjing Jiangning Hospital, Nanjing, China.
  • Ye J; Department of Endocrinology, The Second People's Hospital of Hefei, Hefei, China.
  • Wang Y; Department of Endocrinology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
  • Chen L; Department of Endocrinology, The 2nd Affiliated Hospital of Harbin Medical University, Harbin, China.
  • Sun J; Jilin Huisheng Bio-pharmaceutical Co., Ltd, Beijing, China.
  • Ji L; Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
Diabetes Obes Metab ; 25(3): 785-795, 2023 03.
Article em En | MEDLINE | ID: mdl-36433709
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Resistência à Insulina / Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose / Metformina Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Resistência à Insulina / Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose / Metformina Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article